Nigeria-article-2-header

Our actions today, their future tomorrow: Working together to make sure every patient counts

The following is the second article in a 3-part series about the transformation that has taken place for the bleeding disorders community in Nigeria, thanks to the WFH and our supporters.

Also available in: Français Español

One morning at 2 a.m., Megan Adediran, Founder and Executive Director of the Hemophilia Foundation of Nigeria (HFN), received a call from a mother asking for help: her son had fallen and would not stop bleeding. By 6 a.m. when Adediran called back to check-in, the young man had passed away.

These stories used to be far too common in Nigeria. Fortunately, the tide is turning, in large part because of the training and support that healthcare providers and patient advocates across the country have received from the World Federation of Hemophilia (WFH). In fact, ensuring that they are equipped and working together effectively to support people living with bleeding disorders is a pillar of the WFH’s healthcare development work. “We all know our strengths and weaknesses, and we know that we are here to complement one another for the good of patients, ” explained Adediran.

Partnerships established through the WFH Twinning Program have also had a significant impact in Nigeria. Hemophilia treatment centre (HTC) pairings have been instrumental to establishing multidisciplinary care teams across the country. The partnership between the Abuja National Hospital and the RUSH HTC in Chicago, U.S.A, helped raise awareness of bleeding disorders among healthcare professionals and provided training opportunities for laboratory technicians, nurses, and physicians. A second pairing, between the University of Nigeria Teaching Hospital (UNTH) in Enugu and the Children’s Hospital of Philadelphia (CHOP) HTC in Philadelphia, U.S.A, a few years later led to the identification of 30 people with bleeding disorders, the creation of educational resources for nurses, and the training of more than 25 healthcare workers.

Trained healthcare providers are vital to proper care, but Adediran also recognizes the importance of working closely with the medical community on advocacy efforts. “We have always emphasized that our organization is patient driven, treaters backed. Our healthcare providers are a very important pillar in our growth.” She credits this collaboration as one of the reasons the HFN—with funding and support from the WFH—was able to successfully convene partners from 36 states to a national Stakeholders Forum in 2017. The Federal Ministry of Health, the office of the Commissioner of Health, and WFH representatives gathered there to call for the appointment of desk officers (speakers) in various states. This important step meant that the HFN, and the families they represent, would have a place to turn within government to make their voices heard and to advocate for safe and effective treatment for their community.

Evidence-based data has been another key to the success of Nigeria’s advocacy efforts. “Before 2005, there was no central register for bleeding disorders in Nigeria. Policymakers did not understand the problem,” explained Theresa Nwagha, MD, Consultant Hematologist at the University of Nigeria. “Now every patient counts.” Data collection within HTCs in Nigeria was made possible thanks to the WFH World Bleeding Disorders Registry, which was launched in 2018.

“We can now easily describe the burden of bleeding disorders in our communities, support evidence-based advocacy initiatives and advance the understanding and care of our people with hemophilia,” said Titilope A. Adeyemo, MD, Department of Haematology & Blood Transfusion, College of Medicine, Lagos University Teaching Hospital.

The strong partnership between healthcare providers and the patient community, and the availability of clinical data, are central to the HFN’s ongoing efforts to secure prophylaxis for all children with hemophilia in Nigeria.

“Now, we are asking that the government purchase product to provide prophylaxis to children between zero- to five-years-old, while we continue treating six- to ten-year-olds with product donated from the WFH,” explained Adediran. Despite all the progress that has already been made, the HFN has no plans of slowing down—and the WFH will be there to support them every step of the way.

For nearly 60 years, the WFH has been working to create sustainable change for the global bleeding disorders community. We do this by empowering community leaders and healthcare providers with the knowledge and tools they need to improve the lives of people with bleeding disorders. Our actions today will shape their future tomorrow.

To read about the inspiring transformational narrative of Nigeria’s journey to access to safe treatment, care, and diagnosis, access the first article in the series, here and the third article, here.

I have seen firsthand how the WFH has transformed the lives of people with bleeding disorders by empowering patient advocates and healthcare providers with the knowledge and tools they need to improve lives and work together to advocate for their communities. It’s what motivates me to be a part of the WFH as a volunteer board member and as a donor. Every dollar you contribute gets us one step closer to our vision of Treatment for All.

- Glenn Pierce, MD, PhD, WFH Vice President, Medical

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.